IMMUNOCORE HOLDINGS PLC - AMERICAN DEPOSITARY SHAR

Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma

26 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference

06 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4

06 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the Jefferies London Healthcare Conference

11 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update

10 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

09 Nov 2021 08:01:00 By Nasdaq GlobeNewswire

Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel

18 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine

22 Sep 2021 18:00:00 By Nasdaq GlobeNewswire

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

20 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021

13 Sep 2021 16:30:00 By Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

10 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

08 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

24 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update

11 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

04 Jun 2021 09:05:00 By Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

27 May 2021 16:30:00 By Nasdaq GlobeNewswire

Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B

18 May 2021 16:10:00 By Nasdaq GlobeNewswire

Immunocore Reports First Quarter 2021 Financial Results

12 May 2021 07:00:00 By Nasdaq GlobeNewswire

Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

28 Apr 2021 16:30:00 By Nasdaq GlobeNewswire

Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting

12 Apr 2021 16:30:00 By Nasdaq GlobeNewswire